Besides strong presence in field of oncology, we are deftly dealing with other therapeutic areas presenting unmet medical needs for e.g. multiple sclerosis, immunosuppressant therapies etc. Further to consolidation in field of generic API and formulations, we are now treading on the path to put in our efforts in field of novel drug delivery systems and biotech products such as small peptides. Our oral disintegrating strip for Ondansetron- which is already launched in India has received quite a positive patient and prescriber response. We are further working on many other oral fast dissolving films. We ensure to provide cost reduction without compromising quality standards.
For more information on Shilpa‘s pipeline/products in field of non-oncology therapies and NDDS, please find below our Other Pharma Product List.
|Non-Oncology API||Tech Pack||DMF Status|
|Open Part||US||EU||TPD||PMDA||TGA||EDQM||KFDA||GCC||Medsafe||DMF Number|
|Ambroxol HCl||R1-CEP 2004-201 Rev 02|
|Sildenafil Citrate||DMF Available|
|Ursodeoxycholic acid||from our Italian Principal|
|Phenylephrine HCL||DMF Available|
|Dimethyl Fumarate||DMF Available|
|NOVEL DRUG DELIVERY SYSTEMS UNDER DEVELOPMENT|
|Cytarabine: Lipid Complex Injection|
|Daunorubicin Citrate: Liposomal Injection|
|Doxorubicin Hydrochloride: Liposomal Injection|
|Paclitaxel: Protein bound particles for Injectable Suspension|
* PRODUCTS UNDER VALID PATENTS ARE NOT OFFERED FOR COMMERCIAL OPERATIONS:
ONLY R&D QUANTITIES ARE OFFERED.
For Enquiries, please contact